Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Introduction: Several reports have shown marked heterogeneity of antibiotic pharmacokinetics (PK) in patients admitted to ICUs, which might potentially affect outcomes. Therefore, the pharmacodynamic (PD) parameter of the efficacy of β-lactam antibiotics, that is, the time that its concentration is above the bacteria minimal inhibitory concentration (T > MIC), cannot be safely extrapolated from data derived from the PK of healthy volunteers. Methods: We performed a full review of published studies addressing the PK of intravenous β-lactam antibiotics given to infected ICU patients. Study selection comprised a comprehensive bibliographic search of the PubMed database and bibliographic references in relevant reviews from January 1966 to December 2010. We selected only English-language articles reporting studies addressing β-lactam antibiotics that had been described in at least five previously published studies. Studies of the PK of patients undergoing renal replacement therapy were excluded. Results: A total of 57 studies addressing six different β-lactam antibiotics (meropenem, imipenem, piperacillin, cefpirome, cefepime and ceftazidime) were selected. Significant PK heterogeneity was noted, with a broad, more than twofold variation both of volume of distribution and of drug clearance (Cl). The correlation of antibiotic Cl with creatinine clearance was usually reported. Consequently, in ICU patients, β-lactam antibiotic half-life and T > MIC were virtually unpredictable, especially in those patients with normal renal function. A better PD profile was usually obtained by prolonged or even continuous infusion. Tissue penetration was also found to be compromised in critically ill patients with septic shock. Conclusions: The PK of β-lactam antibiotics are heterogeneous and largely unpredictable in ICU patients. Consequently, the dosing of antibiotics should be supported by PK concepts, including data derived from studies of the PK of ICU patients and therapeutic drug monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Heterogeneity of volume of distribution in litres of β-lactam antibiotics in ICU patients. Open circles: volume of distribution in healthy volunteers [44,51,89-92]; filled squares: weighted means of volume of distribution in the studies; straight lines: ranges of the means of volume of distribution in the studies.](https://figures.cochat.ai/paper-figures/83611cc812e44433b6b33a2cd391c970/antibiotics-in-critically-ill-patients-a-systematic-review-of-the-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beta-lactam antibiotics may be subject to changes in important pharmacokinetic parameters in the setting of sepsis and septic shock resulting in sub-therapeutic concentrations [230, 231].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [230]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Basic & Clinical Biostatistics
Dawson, B. K., & Trapp, R. G. (2004) · Cited by 699
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556 · cited 1×
“Considerable evidence demonstrates that free drug time above bacteria minimal inhibitory concentration (f T > MIC) is the measure of drug exposure most closely linked to the ability of b-lactam antibiotics to kill the target bacteria [4].”
BackgroundThe epidemiology of the systemic inflammatory response
Brun-Buisson, C. (2000) · Intensive Care Medicine · doi:10.1007/s001340051121 · Cited by 534 · cited 1×
“Infection and sepsis, whether community- or hospitalacquired, are important causes of morbidity and mortality in ICU patients [1,2].”
BackgroundFridkin, S. K., Steward, C. D., Edwards, J. R., Pryor, E. R., McGowan, Jr., Archibald, L. K., Gaynes, R. P., & Tenover, F. C. (1999) · Clinical Infectious Diseases · doi:10.1086/520193 · Cited by 486
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock
Taccone, F. S., Laterre, P.-F., Dugernier, T., Spapen, H., Delattre, I., Wittebole, X., De Backer, D., Layeux, B., Wallemacq, P., Vincent, J.-L., et al. (2010) · Critical Care · doi:10.1186/cc9091 · Cited by 369 · cited 2×
“…= 8 mg/L: bolus 70%, CI 100% CFR for EC: bolus 100%, CI 100% CFR for PA: bolus 40.6%, CI 100% Ceftazidime, 2 g 70% T > 4 × EUCAST breakpoint of PA 28% Taccone et al., 2010 [23] Cefepime, 2 g 70% T > 4 × EUCAST breakpoint of PA 16% Meropenem, 1 g 40% T > 4 × EUCAST breakpoint of PA…”
BackgroundInfluentialRoberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Robertson, T. A., Dalley, A. J., & Lipman, J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp139 · Cited by 347 · cited 13×
“…± 4.9 6.7 ± 4.2 3.7 ± 1.9 N = 6 Age 65.7 ± 11.2 years Peritonitis Descriptive Karjagin et al., 2008 [25] Meropenem 22.7 13.6 ± 1.3 NR N = 10 Age range 48 to 63 years Severe sepsis Randomized, parallel controlled Roberts et al., 2009 [24] Meropenem Meropenem 30.1 [21.7 to 53.9]e Meropenem 8 [5 to…”
BackgroundMethodInfluentialTherapeutic drug monitoring of β-lactams in critically ill patients: proof of concept
Roberts, J. A., Ulldemolins, M., Roberts, M. S., McWhinney, B., Ungerer, J., Paterson, D. L., & Lipman, J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.008 · Cited by 334
Pea, F., Viale, P., & Furlanut, M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00002 · Cited by 327 · cited 1×
“Drugs that distribute essentially in the extracellular fluid (mainly hydrophilic) have low Vd, whilst drugs that have rapid cellular uptake (lipophilic) have high Vd[5,6].”
Background
Cited by
Items 301–400 of 409
Stewart, S. D., Allen, S. J., Eisenberg, B., Sakakeeny, K., Hammond, T. N., Schneider, B., Mochel, J. P., & Zhou, T. (2022) · American Journal of Veterinary Research · doi:10.2460/ajvr.22.08.0139 · Cited by 3
Pharmacokinetics in Critically Ill Children with Acute Kidney Injury
Raina, M., Ashraf, A., Soundararajan, A., Mandal, A. K., & Sethi, S. K. (2023) · Pediatric Drugs · doi:10.1007/s40272-023-00572-z · Cited by 3
König, C., Kuti, J. L., & Fratoni, A. J. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70029 · Cited by 5
“5 15 Therapeutic drug monitoring (TDM) is a well-known intervention to optimize antimicrobial therapies and is gaining interest beyond its routine use in guiding vancomycin and aminoglycoside dosing.”
Wieringa, A., ter Horst, P. G. J., Wagenvoort, G. H. J., Dijkstra, A., Abdulla, A., Haringman, J. J., & Koch, B. C. P. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac334 · Cited by 4
Lee, J. M., Lee, J. W., Jeong, T. S., Bang, E. S., & Kim, S. H. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00542-18 · Cited by 3
“times higher, respectively, than those reported in normal healthy subjects (11, 23).”
BackgroundResultThe role of antibiotic pharmacokinetic studies performed post-licensing
Parker, S. L., Abdul-Aziz, M. H., & Roberts, J. A. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106165 · Cited by 6
Mieresová, M., Balazova, K., Kubele, J., Cerny, D., & Halačová, M. (2023) · Clinical Case Reports · doi:10.1002/ccr3.7032 · Cited by 3
Antibiotic Dosing During Extracorporeal Membrane Oxygenation
Abdul-Aziz, M. H., Shekar, K., & Roberts, J. A. (2017) · Springer eBooks · doi:10.1007/978-981-10-5336-8_8 · Cited by 3
Accuracy in diagnosis of allergy to β-lactams
Iglesias-Souto, J., González‐Pérez, R., Guedes, P. P., Sánchez‐Machín, I., & Matheu, V. M. (2012) · Critical Care · doi:10.1186/cc11193 · Cited by 3
“Iglesias-Souto et al. Critical Care 2012, 16:414 http://ccforum.com/content/16/2/414 Table 1.”
InfluentialAntibiotic dosing and concentration variability during continuous renal replacement therapy
Alexander, E. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e3182451fc5 · Cited by 3
“For instance, both interpatient and intrapatient heterogeneity exists with a number of antibiotics in critically ill patient populations with or without renal impairment (3).”
BackgroundAdamiszak, A., Bartkowska‐Śniatkowska, A., Grześkowiak, E., & Bienert, A. (2024) · Anaesthesiology Intensive Therapy · doi:10.5114/ait.2024.141332 · Cited by 2
“Furthermore, due to the reported high values of volume of distribution and clearance and the low protein-bound fraction, high variability of PK parameters is observed between different populations [33].”
BackgroundTruong, A. Q., Smeets, T. J. L., Terrier, J. E., Li, L., Co, D. X., Strojil, J., Preijers, T., Koch, B. C. P., Huttner, A., & Sassen, S. D. T. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.05.005 · Cited by 4
Bastin, M. L. T., Rech, M. A., Betthauser, K. D., Heavner, M. S., Horng, M., Lemieux, S. M., Lumpkin, M., McCreary, E. K., Ruggero, M. A., Wieruszewski, P. M., et al. (2025) · CMI Communications · doi:10.1016/j.cmicom.2025.105084 · Cited by 3
Lacquaniti, A., Pistolesi, V., Smeriglio, A., Santoro, D., Iannetti, C., Lentini, G., Chimenz, R., Chirico, V., Trombetta, D., Morabito, S., et al. (2025) · Antibiotics · doi:10.3390/antibiotics14111097 · Cited by 2
Beta-lactam dose reductions in critically ill patients with acute kidney injury: a scoping review
Horstink, M. M. B., Rietdijk, W. J. R., Geel, D. R., Deetman, P. E., Endeman, H., Koch, B. C. P., & den Uil, C. A. (2025) · Critical Care · doi:10.1186/s13054-025-05736-6 · Cited by 2
Matusik, É., Lambiotte, F., Toné, A., & Lemtir, J. (2020) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2020.11.011 · Cited by 4
Antibiotics in anesthesia and critical care
Premachandra, A., & Moine, P. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-5585 · Cited by 3
“Likewise, there is little evidence and no consensus regarding AP in a patient with past infection/ colonization with MDROs, nor in patients with risk factors for MDROs (12,116).”
InfluentialChen, J., Wang, Q., Li, S., Han, R., Wang, C., Cheng, S., Yang, B., Diao, L., Yang, T., Sun, D., et al. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.07.001 · Cited by 2
Isotope-dilution-LC-MS/MS candidate reference measurement procedure for cefepime in human serum
Schäffler, J., Vogeser, M., & Habler, K. (2024) · Journal of Mass Spectrometry and Advances in the Clinical Lab · doi:10.1016/j.jmsacl.2024.08.001 · Cited by 2
“This concerns especially critically ill patients, patients with or suspected renal dysfunction, and those with suspected risk for neurotoxicity [16 – 18].”
Chihara, S., Ishigo, T., Kazuma, S., Matsumoto, K., Morita, K., & Masuda, Y. (2024) · Antibiotics · doi:10.3390/antibiotics13080755 · Cited by 2
“In critically ill patients undergoing CRRT, the increase in the volume of distribution can be explained by the fluid overload associated with sepsis-induced capillary leak syndrome [32,33].”
BackgroundInfluentialMolina, F., Agudelo, C. A., Fonseca-Ruiz, N. J., Hidrón, A., Jiménez, C. A., Ochoa, Á., Restrepo, C. A. A., Trompa, I. M., & Roncancio, G. E. (2015) · Acta Colombiana de Cuidado Intensivo · doi:10.1016/j.acci.2015.11.001 · Cited by 2
Toullec, L., Dupouey, J., Vigne, C., Marsot, A., Allanioux, L., Blin, O., Léone, M., & Guilhaumou, R. (2017) · Therapies · doi:10.1016/j.therap.2017.02.003 · Cited by 2
Xu, J. H., Cheng, V., Rawlins, M. D. M., Lennon, J., Morgan, D. J. R., McWhinney, B. C., Ungerer, J. P. J., Wilde, A., Dyer, J. R., & Roberts, J. A. (2020) · EMJ Nephrology · doi:10.33590/emjnephrol/20-00078 · Cited by 2
Mitton, B. C., Paruk, F., Gous, A. G., Chausse, J., Milne, M., Becker, P., & Said, M. (2022) · South African Medical Journal · doi:10.7196/samj.2022.v112i9.16371 · Cited by 3
“Interestingly, we found a poor correlation between the two variables that is clearly illustrated by Figs 1 and 2 and supports the findings and conclusions of previous reports that imipenem levels are not predictable in critically ill patients.[17,34,40,41] The result suggests that there are other factors influencing t…”
Resultvan Gelder, T. G., Schweitzer, V. A., Uijtendaal, E. V., & Sikma, M. A. (2024) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001215 · Cited by 2
Population pharmacokinetics of meropenem in Vietnamese adult patients
Thủy, N. T. T., Thanh, D. D., Ha, N. H., & Hương, N. T. L. (2018) · Pharmaceutical Sciences Asia · doi:10.29090/psa.2018.04.017.0042 · Cited by 2
“The additive error model, the proportional error model, the exponential error model, the combined additive and proportional model, the combined additive and exponential model, as shown in following equation (3) - (7), were evaluated to describe the residual variability.”
MethodAntibiotic dosing in the critically ill: asking the same questions but expecting different answers
Póvoa, P. M. S. R., Spriet, I., & Zahar, J. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3477-3 · Cited by 2
Self-citationUnraveling the Impact of Therapeutic Drug Monitoring via Machine LearningPreprint
Ates, H. C., Alshanawani, A., Hagel, S., Cotta, M. O., Roberts, J. A., Dincer, C., & Ateş, C. (2023) · medRxiv · doi:10.1101/2023.10.23.23297424 · Cited by 2
Pharmacokinetics and Pharmacodynamics of Antibiotics in Transplant Patients
Schoeppler, K. E., Mueller, S. W., & Barber, G. R. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_51 · Cited by 2
Omar, A., Asmar, B. I., Ang, J. Y., Salimnia, H., Thomas, R., & Abdel‐Haq, N. (2024) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000004650 · Cited by 3
“32,33 In our study, antibiotics were given intermittently (alone or in combination), and the antibiotic duration of each antibiotic represents the cumulative number of days during which that antibiotic was administered.”
Farinella, A., Salvagno, M., Minini, A., Attanasio, L., Cunha, A., Menozzi, M., Saravia, A., Amado, F., Gorham, J., Hites, M., et al. (2025) · Life · doi:10.3390/life15050739 · Cited by 1
“Beta-lactam antibiotics are the most frequently used antimicrobials in critically ill patients [15], due to their broad-spectrum activity, wide therapeutic index and safety profiles [16].”
Tian, S., Chen, Y., Qiu, M., Wu, W., Dou, L., Wang, J., Xu, L., Zhou, Z., Wu, M., Li, J., et al. (2025) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-025-05343-x · Cited by 2
El-hamd, N. E. A., Hasaneen, M. N. A., El-Sayed, A. K. A., Abou-Dobara, M. I., Ateya, A. I., & Omer, A. M. (2026) · Nano Biomedicine and Engineering · doi:10.1016/j.nbe.2025.100023 · Cited by 1
Bergmann, F., Prager, M., Pracher, L., Kumpf, K., Zeitlinger, M. A., & Jorda, A. (2026) · Annals of Intensive Care · doi:10.1016/j.aicoj.2025.100022 · Cited by 1
“However, critical illness is frequently accompanied by pathophysiological alterations in renal function, tissue distribution, and organ performance that may affect pharmacokinetics and thereby impair the efficacy of antimicrobials [4].”
Rolsma, S. L., Blackman, M. H., Beck, C., Dbouk, A., Morovia, F., Glover, F., Ess, G., Dohler, K., Bridges, B. C., Choi, L., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag069 · Cited by 1
Inamdar, A., Beeraka, N. M., Vikram, P. R. H., Gurupadayya, B. M., Sanathan, S. R., Prashant, A., Kumar, T. P., Nikolenko, V. N., Reddy, Y. P., Kandula, D. R., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1761582 · Cited by 3
Lidén, M. M., Boroli, F., von Dach, E., Lescuyer, P., Tonoli, D., Huttner, A. C., the OPTIMAL TDM Study Group, Karmime, A., Bourgeois-Pfister, R., Harbarth, S., et al. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag242 · Cited by 1
Bondareva, I. B., Zyryanov, S. K., & Станиславович, Ч. М. (2022) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2021-66-11-12-31-38 · Cited by 1
Molina, F., González, M., Guerra, A. D., Muñoz, F., & Mendoza, R. (2016) · Acta Colombiana de Cuidado Intensivo · doi:10.1016/j.acci.2016.03.002 · Cited by 1
Zavrelova, A., Radocha, J., Paterová, P., Žák, P., Víšek, B., & Šíma, M. (2022) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2023.001 · Cited by 1
“pharmacokinetic/pharmacodynamic target for critical patients with 100% plasma concentration time above minimal inhibitory concentration (MIC).(26) It is probably even better when plasma drug concentration is 4 times higher for 100% time than MIC.”
BackgroundKadralinova, A., Bekniyazova, A. Z., Konkayeva, M. E., Yeltayeva, A. A., & Konkayev, A. K. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1148555 · Cited by 1
Performing clinical drug trials in acute and critically ill neonates and children
Cock, P. A. J. G. D., Smits, A., Oualha, M., Stitt, G. A., Metsvaht, T., Smeets, N. J. L., Allegaert, K., Turner, M. A., Amigoni, A., Zuppa, A. F., et al. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88459-4.00018-3 · Cited by 1
Chen, J., Wang, Q., Li, S., Han, R., Wang, C., Cheng, S., Yang, B., Diao, L., Yang, T., Sun, D., et al. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.12.002 · Cited by 1
Piperacillin-Tazobactam Strikes Again: A Neutropenic Mystery Unraveled
Ramalingam, P., Nasser, Z., Patel, K., & Dabak, V. S. (2025) · Cureus · doi:10.7759/cureus.93189 · Cited by 1
“It is particularly effective in the treatment of infections caused by beta-lactamase-producing bacteria [2,3].”
Hospital-acquired pneumonia and its management
Schellack, N., & Schellack, G. (2015) · Pharmacy management · Cited by 1
Pharmacokinetic and Pharmacodynamic Tools to Increase Efficacy
Sinnollareddy, M., Cotta, M. O., & Roberts, J. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-810477-4.00007-6 · Cited by 1
Sepsis-Update: evidenzbasierte Therapie
Märtin, L., Bickenbach, J., & Marx, G. (2019) · AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie · doi:10.1055/a-0625-5521 · Cited by 1
Is it possible to shorten serum bactericidal testing?
Paterová, P., Radocha, J., Buchta, V., Zavrelova, A., Maláková, J., Pavel, Ž., & Žemličková, H. (2019) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2019.105775 · Cited by 1
Conceptual model of adding antibiotics to dialysate fluid during renal replacement therapy
Bartuševiciene, I., Vicka, V., Vickienė, A., Tetianec, L., Dagys, M., Ringaitienė, D., Klimašauskas, A., & Šipylaitė, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-03450-1 · Cited by 1
Roux, D., Bénichou, N., Hajage, D., Martin‐Lefèvre, L., de Prost, N., Lerolle, N., Beauport, D. T., Boulet, É., Mayaux, J., Mégarbane, B., et al. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01105-0 · Cited by 1
Antibiotics, Antivirals, and Antifungals in Critical Care
Shamshirsaz, A. A., & Vaught, A. “. J. (2024) · Wiley eBooks · doi:10.1002/9781119820260.ch19 · Cited by 1
Rationale antibiotische Therapie beim Multiorganversagen
Bollmann, J., & Langgartner, J. (2013) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Synthesis of Multiply Deuterated Cephalosporins
Teckwani, K. N. (2014) · UWSpace (University of Waterloo)
May an “Early” Renal Replacement Therapy Improve Survival?
Monti, G., Greco, M., & Cabrini, L. (2016) · Springer eBooks · doi:10.1007/978-3-319-33429-5_5
Abdul-Aziz, M. H. (2016) · The University of Queensland · doi:10.14264/uql.2016.450
“Large Vd and CL differences are common [56, 181].”
BackgroundInfluentialGeneric and Optimized Antibacterial Dosing Strategies in the Critically Ill
Waele, J. J. D. (2017) · Springer eBooks · doi:10.1007/978-981-10-5336-8_10
Improving antibiotic dosing in critically ill Australian Indigenous patients with severe sepsis
Tsai, D. (2017) · The University of Queensland · doi:10.14264/uql.2017.481
Prolonged Infusion of Beta-lactam Antibiotics in Critically Ill Patients: Revisiting the Evidence
Dhaese, S. A. M., Stove, V. V., & Waele, J. J. D. (2018) · Annual update in intensive care and emergency medicine · doi:10.1007/978-3-319-73670-9_5
Kupa, L. D. V. K. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2019.tde-09082019-141343 · Cited by 1
Barton, G. (2019) · Liverpool John Moores University · doi:10.24377/ljmu.t.00011543
“, 1990; Grace, 2012) but there are no prospective studies showing patientorientated benefits (Roberts et al., 2008b; Gonçalves-Pereira and Póvoa, 2011) and the use of continuous infusion is still generally not well studied in the critically ill population with just one”
BackgroundImpact of High Body Weight on Mortality in Critically Ill Patients Receiving Meropenem for Pneumonia
Gao, X., Liang, L., & Yan, P. (2019) · Cureus · doi:10.7759/cureus.6403
“The increased Vd and Cl can lead to a substantially lower serum concentrations of carbapenems in those patients [11].”
BackgroundSumi, C. D. (2020) · The University of Queensland · doi:10.14264/uql.2020.871
Ceftaroline removal during plasmapheresis
Bonaga, B., Montori, L. S., Barceló‐Vidal, J., & Grau, S. (2021) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2021.09.008
(2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32835af239
Ceftaroline removal during plasmapheresis
Bonaga, B., Montori, L. S., Barceló‐Vidal, J., & Grau, S. (2022) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2021.09.013
Hagel, S., Forstner, C., Welte, T., & Pletz, M. W. (2015) · Springer eBooks · doi:10.1007/978-3-662-45148-9_6
(2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu336
Anderson, T. (2016) · Springer eBooks · doi:10.1007/978-3-319-44034-7_6
Pathogenesis of Bacterial Infections and Bacterial Persistence
Cobo, F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00098-7
Correia, P. A., Launay, M., Balluet, R., Gergelé, L., Gauthier, V., Morel, J., Beuret, P., Mariat, C., Thiéry, G., & Ragey, S. P. (2023) · Research Square · doi:10.21203/rs.3.rs-2515214/v1
Farmakokinetika Dan Pendosisan Gentamisin Pada Pasien Pediatri
Risky, B. (2023) · Jurnal Farmasi Tinctura · doi:10.35316/tinctura.v4i2.2620
Launay, M., Ollier, É., Kably, B., Louedec, F. L., Thiéry, G., Lanoiselée, J., & Ragey, S. P. (2023) · Research Square · doi:10.21203/rs.3.rs-3748918/v1
Launay, M., Ollier, É., Kably, B., Louedec, F. L., Thiéry, G., Lanoiselée, J., & Périnel, S. (2024) · Antibiotics · doi:10.3390/antibiotics13080756
“Moreover, CAZ excretion is mainly renal and septic critical illness can lead to modified renal clearance (CL) [2].”
BackgroundUV Raman spectroscopy for therapeutic drug monitoring
Frosch, T., Domes, C., Popp, J., & Frosch, T. (2024) · UV and Higher Energy Photonics: From Materials to Applications · doi:10.1117/12.3028022
“However, critical illness can cause significant pathophysiological changes that alter the pharmacokinetics of antibiotics 3, 4 , making it difficult to predict the correct dosing scheme of drugs 5, 6 .”
Hou, J., Zhao, Y., Luo, H., Li, J., Xiao, Y., Gong, H., Ma, R., Cai, H., Zhang, B., & Yan, M. (2024) · Research Square · doi:10.21203/rs.3.rs-5712217/v1
Domes, C., Graul, L., Frosch, T., Popp, J., Hagel, S., Pletz, M. W., & Frosch, T. (2025) · Communications Medicine · doi:10.1038/s43856-025-00823-9
“However, the pathology of critically ill patients may cause physiological changes that grossly alter the pharmacokinetics of antimicrobial substances 1,7 and complicate the prediction of drug exposure 8,9 .”
Target attainment of benzylpenicillin in patients with infective endocarditis
Bock, M., van Hasselt, J. G. C., Fuursted, K., Ihlemann, N., Gill, S. U. A., Christiansen, U., Bruun, N. E., Elming, H., Povlsen, J. A., Køber, L., et al. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.04.025 · Cited by 1
Nouh, M. I., AlButi, H., Karrar, H. R., Hassan, D. M., Alhendi, R. S. A., Aseeri, H. A., Algothmi, M. A., Almuqati, A. O., Alotaibi, K. M., Alkhaifi, N. M., et al. (2025) · Cureus · doi:10.7759/cureus.86262
“This broad-spectrum effectiveness solidifies meropenem's role as a standard treatment choice for various intra-abdominal infections, highlighting its importance in the ever-evolving landscape of antibiotic therapy for serious infections [9-13].”
Wang, X., Ke, H., Zhu, J., Zhao, L., Liu, Y., He, Y., Wu, W., & Yu, H. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00962-8
Sun, J., Yang, C., Tang, B., Hao, G., van den Anker, J. N., Wu, Y., Sun, D., Zheng, Y., & Zhao, W. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70089
“14 Empirical doses of β -lactam antibiotics might result in suboptimal plasma concentrations.”
Infections en réanimation : que peut-on améliorer ?
Dahmane, L. (2022) · Médecine et Maladies Infectieuses Formation · doi:10.1016/s2772-7432(22)00477-9
Zhao, Y., Liu, J., Li, J.-K., Liu, H.-Y., Sun, Z., Zhang, B., & Yan, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1725419
Barreto, E. F., Rule, A. D., Al‐Shaer, M. H., Roberts, J. A., Abdul-Aziz, M. H., Scheetz, M. H., Mara, K. C., Jannetto, P. J., Gajic, O., O’Horo, J. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14302569
Roux, D., Bénichou, N., Hajage, D., Martin‐Lefèvre, L., de Prost, N., Lerolle, N., Beauport, D. T., Boulet, É., Mayaux, J., Mégarbane, B., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22603108
Pařízková, R. Č., Martínková, J., Havel, E., Šafránek, P., Kaška, M., Astapenko, D., Bezouška, J., Chládek, J., & Černý, V. (2021) · Figshare · doi:10.6084/m9.figshare.15000155
Roux, D., Bénichou, N., Hajage, D., Martin‐Lefèvre, L., de Prost, N., Lerolle, N., Beauport, D. T., Boulet, É., Mayaux, J., Mégarbane, B., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22603111
Barreto, E. F., Rule, A. D., Al‐Shaer, M. H., Roberts, J. A., Abdul-Aziz, M. H., Scheetz, M. H., Mara, K. C., Jannetto, P. J., Gajic, O., O’Horo, J. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14302566
Laporte-Amargós, J., Gudiol, C., Arnan, M., Puerta‐Alcalde, P., Carmona-Torre, F., Huguet, M., Albasanz‐Puig, A., Parody, R., Garcia-Vidal, C., del Pozo, J. L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12324617
Barreto, E. F., Rule, A. D., Al‐Shaer, M. H., Roberts, J. A., Abdul-Aziz, M. H., Scheetz, M. H., Mara, K. C., Jannetto, P. J., Gajic, O., O’Horo, J. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14302563
Sieswerda, E., Bax, H. I., Hoogerwerf, J. J., de Boer, M. G. J., Boermeester, M. A., Bonten, M. J. M., Dekker, D., van Wijk, R. G., Juffermans, N. P., Kuindersma, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20479548
Are we overlooking a hidden organ in sepsis-associated AKI?
Lydon, E., Liu, K. D., & Calfee, C. S. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamaf098
Dubinsky, S., McIntyre, M. T., Kim, M., Hawryluck, L., & Edginton, A. N. (2026) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-025-00981-0
Abdalla, S., Royer, W., Béranger, A., Benaboud, S., Heilbronner, C., Bournaud, L. F., Lopez-Lopez, V., Sanoufi, M. R., Léger, P., Khemakhem, M., et al. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag019
Abdul-Aziz, M. H., Cheng, V., Burrows, F. S., Buscher, H., Cho, Y., Corley, A., Diehl, A., Gilder, E., Kim, H.-S., Levkovich, B., et al. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag090
Zhang, Y., Oritz-Balsero, A. S., Bulut, E., Li, X., Schmidt, A. M., Schmidt, J. W., Arthur, T. M., & Wang, B. (2026) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2026.111751
Pharmacokinetics of Intravitreal Vancomycin and Ceftazidime in Silicone Oil-Filled Macaque Eyes.
今村拓, KAKINOKI, M., Taira, T., 寺田, 智., 河本, 育., 村瀬, 充., 大路, 正., Imamura, T., Hira, D., Kitagawa, T., et al. (n.d.) · Institutional Repositories DataBase (IRDB)
Lucchetti, J., Fracasso, C., Cesana, D., Dore, F., Finazzi, S., & Gobbi, M. (2026) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2026.117514
Riese, T., Lauter, S., Surat, G., Kurlbaum, M., Roeder, D., Meybohm, P. M., & Hoppe, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1725502
Metadata
- Authors
- Gonçalves-Pereira, J., & Póvoa, P.
- Affiliations
- University of Lisbon (PT)
- ORCID
- Póvoa, Pedro
- Venue
- Critical Care
- Published
- 2011-09-13
- Volume
- 15
- Issue
- 5
- Pages
- R206-R206
- ISSN
- 1364-8535 (ISSN-L)
- PMC
- PMC3334750
- OpenAlex
- W2070242840
- Semantic Scholar
- 028a21fcf10a276ab1fc87191ee4ae66b704ce5e
- Cited by
- 408
- References
- 93
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 26 · 2023: 36 · 2022: 32 · 2021: 43 · 2020: 27 · 2019: 22 · 2018: 24 · 2017: 25 · 2016: 27 · 2015: 26 · 2014: 31 · 2013: 17 · 2012: 21
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Critical Care (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- beta-lactam antibiotics, antibiotic pharmacokinetics, critically ill patients, intensive care unit, volume of distribution, drug clearance, creatinine clearance, half-life, time above MIC, pharmacodynamics, continuous infusion, septic shock, tissue penetration, therapeutic drug monitoring, antibiotic dosing, meropenem, imipenem, piperacillin, cefpirome, cefepime, ceftazidime
- MeSH terms
- Cefepime, Meropenem, Cefpirome, Anti-Bacterial Agents, Ceftazidime, Cephalosporins, Humans, Infections, Piperacillin, Thienamycins, Imipenem, Critical Illness, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.